

Blinatumomab

for newly diagnosed B-precursor acute lymphoblastic leukaemia in the consolidation phase of chemotherapy

Technology Guidance from the MOH Drug Advisory Committee

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

- ✓ Blinatumomab 35 mcg powder for infusion for treating newly diagnosed patients with CD-19-positive B-precursor acute lymphoblastic leukaemia in the front-line consolidation phase of multiphase chemotherapy with documented complete remission (CR) or CR with incomplete haematologic recovery (CRi) after induction therapy for a maximum of four cycles in total.

in view of acceptable clinical effectiveness and safety, and an acceptable pricing proposal by the company.

Funding status

Blinatumomab 35 mcg powder for infusion is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 April 2026.

Clinical indication, subsidy class and MediShield Life claims eligibility for blinatumomab are provided in the Annex.

ANNEX

Recommendations by the MOH Drug Advisory Committee

Drug preparation	Approved clinical indication	Subsidy class (implementation date)	Eligible for MediShield Life claims (implementation date)
Blinatumomab 35 mcg powder for infusion	<p>Treatment of newly diagnosed patients with CD-19-positive B-precursor acute lymphoblastic leukaemia in the front-line consolidation phase of multiphase chemotherapy with documented complete remission (CR) or CR with incomplete haematologic recovery (CRi) after induction therapy for a maximum of four cycles in total.</p> <p>CR is defined as a patient who has:</p> <ul style="list-style-type: none"> (a) 5% or less bone marrow blasts; and (b) no evidence of disease; and (c) a full recovery of peripheral blood counts with platelet count of more than or equal to 100,000 per microlitre; and (d) absolute neutrophil count (ANC) of more than or equal to 1,000 per microlitre. <p>CRi is defined as a patient who: meets all the criteria for CR except without recovery of platelet count (platelets less than 100,000 per microlitre and ANC more than or equal to 1,000 per microlitre) or without recovery of ANC (platelets more than or equal to 100,000 per microlitre and ANC less than 1,000 per microlitre).</p>	MAF (1 April 2026)	Yes ¹ (1 April 2026)

Abbreviations: MAF, Medication Assistance Fund.

¹ Please refer to [MOH's website](#) for the MediShield Life claim limit starting from the implementation date.

VERSION HISTORY

Guidance on blinatumomab for newly diagnosed B-precursor acute lymphoblastic leukaemia in the consolidation phase of chemotherapy

This Version History is provided to track any updates or changes to the guidance following the first publication date. It is not part of the guidance.

Publication of guidance

Date of Publication 6 Feb 2026

Guidance updated to reflect MediShield Life claims eligibility

Date of Publication 1 Jun 2026

 Agency for Care Effectiveness - ACE  Agency for Care Effectiveness (ACE)

About the Agency

The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidance, and education.

As the national HTA agency, ACE conducts evaluations to inform government funding decisions for treatments, diagnostic tests and vaccines, and produces guidance for public hospitals and institutions in Singapore.

The guidance is not, and should not be regarded as, a substitute for professional or medical advice. Please seek the advice of a qualified healthcare professional about any medical condition. The responsibility for making decisions appropriate to the circumstances of the individual patient remains with the healthcare professional.

Find out more about ACE at <https://www.ace-hta.gov.sg/about-us/>

© Agency for Care Effectiveness, Ministry of Health, Republic of Singapore

All rights reserved. Reproduction of this publication in whole or in part in any material form is prohibited without the prior written permission of the copyright holder. Requests to reproduce any part of this publication should be addressed to:

Agency for Care Effectiveness, Ministry of Health, Singapore
Email: ACE@moh.gov.sg

In citation, please credit "Agency for Care Effectiveness, Ministry of Health, Singapore" when you extract and use the information or data from the publication.